VivoSim Labs (VIVS) Operating Income (2011 - 2026)
VivoSim Labs (VIVS) posted Operating Income of -$2.8 million for Q2 2026, up 13.43% on a QoQ basis from -$3.2 million in Q1 2026, and up 5.35% year-over-year from -$2.6 million in Q2 2025.
Analysis
VivoSim Labs (VIVS) Operating Income (2011 - 2026) Analysis & Trends
VivoSim Labs has reported Operating Income for 16 years, with the latest figure at -$2.8 million in Q2 2026.
- On a quarterly basis, Operating Income rose 5.35% year-over-year to -$2.8 million in Q2 2026; TTM through Jun 2026 was -$11.3 million, a 6.7% increase from a year earlier, with the FY2026 full-year figure at -$11.5 million, up 8.95% from the prior year.
- Operating Income was -$2.8 million for Q2 2026 at VivoSim Labs, up from -$3.2 million in the prior quarter.
- The five-year high for Operating Income was -$1.9 million in Q1 2022, with the low at -$7.8 million in Q1 2023.
- Average Operating Income over 5 years is -$3.4 million, with a median of -$3.2 million recorded in 2022.
- The sharpest annual moves came in 2023 and 2024: Operating Income sank 306.64% in 2023, then jumped 60.2% in 2024.
- Over 5 years, Operating Income stood at -$3.4 million in 2022, then declined by 9.56% to -$3.7 million in 2023, then grew by 5.76% to -$3.5 million in 2024, then advanced by 20.7% to -$2.8 million in 2025, then retreated by 0.33% to -$2.8 million in 2026.
- The last three Operating Income figures came in at -$2.8 million (Q2 2026), -$3.2 million (Q1 2026), and -$2.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 506.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 146.82 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 137.83 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 119.89 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 14.80 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | -58.55 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | -409,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | -6.00 Bn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -2.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.76 Mn |
| Mar 31, 2026 | -3.19 Mn |
| Dec 31, 2025 | -2.75 Mn |
| Sep 30, 2025 | -2.64 Mn |
| Jun 30, 2025 | -2.92 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Sep 30, 2024 | -2.61 Mn |
| Jun 30, 2024 | -3.39 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -3.68 Mn |
| Sep 30, 2023 | -4.12 Mn |
| Jun 30, 2023 | -4.20 Mn |
| Mar 31, 2023 | -7.78 Mn |
| Dec 31, 2022 | -3.36 Mn |
| Sep 30, 2022 | -3.35 Mn |
| Jun 30, 2022 | -3.24 Mn |
| Mar 31, 2022 | -1.91 Mn |
| Dec 31, 2021 | -3.50 Mn |
| Sep 30, 2021 | -3.51 Mn |